Amendments to the Claims

1. (currently amended) A compound represented by formula (I);



(I)

wherein;

R and R' are independently C_1-C_5 alkyl, or together R and R' form a saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms;

R_{PH} is hydrogen or methyl;

R1 and R2 are independently hydrogen, halo, or C_1-C_5 alkyl;

L_1 is $-(CH_2)_m-O-$;

L_2 is $-(CH_2)_mCH(OH)-$ or $-(CH_2)_mC(O)-$;

where m is 0, 1 or 2,

R_B is a branched C_3-C_5 alkyl,

R_C is:

$-O-SO_2-(R50)$ where R50 is $-C_{1-3}$alkyl, ~~$-CF_3$,~~ or $-(CH_2)_{1-2}CF_3$;

$-NH-SO_2-(R50)$, where R50 is $-C_{1-3}$alkyl, $-CF_3$, or $-(CH_2)_{1-2}CF_3$;

$-N(CH_3)-SO_2-C_{1-2}$alkyl; or

$-N(SO_2R51)_2$ where each R51 is independently, $-C_{1-3}$alkyl, $-CF_3$, or $-(CH_2)_{1-2}CF_3$.

2. (previously presented) A compound according to Claim 1 wherein R_{PH} is hydrogen.

3-4. (canceled)

5. (currently amended) A compound according to Claim 1 represented by the structural formulae ~~M-1 to M-31~~ below as follows:

M-1)



,

M-2)



,

M-3)



,

~~M-4)~~



;

~~M-5)~~



;

M-6)



,

M-7)



,

M-8)



,

M-9)



,

M-11)



,

M-12)



;

M-13)



,

M-14)



,

M-15)



,

M-16)



,

M-17)



,

M-18)



,

M-19)



, or

M-20)



.

~~M-22)~~



;

~~M-23)~~



;

~~M-24)~~



;

~~M-25)~~



;

~~M-28)~~



;

~~M-29)~~



~~;~~

~~M-30)~~



~~; or~~

~~M-31)~~



~~.~~

6. (previously presented) A compound represented by the structural formulae M-32 to M-50 as follows:

M-32)



,

M-34)



,

M-35)



,

M-36)



,

M-37)



,

M-38)



,

M-39)



,

M-40)



,

M-41)



,

M-42)



,

M-43)



,

M-44)



,

M-45)



,

M-46)



,

M-47)



,

M-48)



,

M-49)



, or

M-50)



.

7. (canceled)

8. (original) A compound represented by a formula below:



.



, or



.

9-15. (canceled)

16. (previously presented) A pharmaceutical formulation comprising the compound according to Claim 1 together with a pharmaceutically acceptable carrier or diluent.

17-18. (canceled)

19. (original) A formulation for treating psoriasis comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 1;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

a. topical glucocorticoids ,

b. salicylic acid,

c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

20. (canceled)

21. (previously presented, withdrawn) A method of treating a mammal for Osteoporosis, Psoriasis, Scleroderma, or seborrheic dermatitis wherein the method comprises administering a

pharmaceutically effective amount of at least one compound of claim 1.

22. (withdrawn) The method of claim 21 for the treatment of psoriasis.

23. (withdrawn) The method of claim 21 for the treatment of osteoporosis.

24-25. (canceled)

26. (previously presented, withdrawn) A method of treating states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound according to claim 1.

27-32. (canceled)

33. (previously presented) A compound represented by formula (II) or a pharmaceutically acceptable salt thereof:



(II)

wherein;

R2 and R2' are independently methyl or ethyl;

R21 and R22 are independently selected from: hydrogen, methyl, ethyl, or -Cl,

$R2_B$ is 3,3-dimethyl-2-hydroxybutoxy or 3,3-dimethyl-2-oxobutoxy; and

$R2_C$ is



where Q is –O- or –NH-.

34. (previously presented) A compound represented by formula (III) or a pharmaceutically acceptable salt thereof:



wherein;

R3 and R3' are independently methyl or ethyl;

R31 and R32 are independently selected from: hydrogen, methyl, ethyl, or -Cl,

$R3_B$ is 3,3-dimethyl-2-hydroxybutoxy or 3,3-dimethyl-2-oxobutoxy; and

$R3_C$ is



or



35. (previously presented) A compound represented by a formula below:



36. (previously presented) A compound represented by a formula below:



37. (previously presented) A compound represented by a formula below:



38. (previously presented) A pharmaceutical formulation comprising the compound according to one of claims 35, 36 or 37 together with a pharmaceutically acceptable carrier or diluent.

39. (previously presented, withdrawn) A method of treating a mammal for Osteoporosis, Psoriasis, Scleroderma, or seborrheic dermatitis wherein the method comprises administering a pharmaceutically effective amount of at least the compound of according to one of claims 35, 36, or 37.

40. (previously presented, withdrawn) The method of claim 39 for the treatment of psoriasis.

41. (previously presented, withdrawn) The method of claim 39 for the treatment of osteoporosis.